Efficacy of enrofloxacin for the treatment of acute clinical mastitis caused by Escherichia coli in dairy cows.
Evidence for the efficacy of antimicrobial treatments in Escherichia coli mastitis is limited. The aim of this double-blinded field trial was to investigate the efficacy of enrofloxacin compared with placebo, with a special focus on survival, in dairy cows with acute clinical mastitis caused by E. coli. Dairy cows (n=116) with acute clinical mastitis were included in the study. A clinical examination was performed and a milk sample from the affected udder quarter was collected for investigation of somatic cell count (SCC) and bacteriology on the first day of treatment (day 0) and at day 3 (clinical examination only), day 22 and day 28. Data regarding culled cows, SCC and daily milk yield were retrieved from monthly milk recording each month until 180 days after treatment. All cows were treated with either enrofloxacin or placebo once a day for three days, starting at day 0. After culturing, 56 cows with confirmed E. coli mastitis remained in the study. Nine (16 per cent) of them died within the first week. Enrofloxacin-treated cows had lower SCC compared with placebo-treated cows at first monthly milk recordings after being treated for mastitis. Treatment with enrofloxacin did not result in a higher probability of survival compared with placebo.
Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute, Uppsala 751 89, Sweden Växa Sverige, Box 210, Stockholm 101 24, Sweden.
Y
Y
Persson
Knowledge Center for Agriculture, Cattle, Agro Food Park 15, Skejby, Aarhus N DK 8200, Denmark.
J
J
Katholm
Växa Sverige, Box 210, Stockholm 101 24, Sweden.
H
H
Landin
Växa Sverige, Box 210, Stockholm 101 24, Sweden.
M J
MJ
Mörk
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002417:Cattle; D002452:Cell Count / Q000662:veterinary; D004311:Double-Blind Method; D000077422:Enrofloxacin; D004926:Escherichia coli / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000150:complications / Q000662:veterinary*; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005500:Follow-Up Studies; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000382:microbiology; D008892:Milk / Q000166:cytology / Q000382:microbiology; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000077422:Enrofloxacin
Antimicrobials; Cattle; Escherichia coli; Mastitis; Treatment